MRUS - Merus NV Stock Price, Fair Value and News

41.92USD-0.05 (-0.12%)Delayed as of 25 Apr 2024, 10:10 am ET

Market Summary

USD41.92-0.05

Delayedas of 25 Apr 2024, 10:10 am

-0.12%

MRUS Stock Price

View Fullscreen

MRUS RSI Chart

MRUS Valuation

Market Cap

2.4B

Price/Earnings (Trailing)

-15.68

Price/Sales (Trailing)

55.27

EV/EBITDA

-14.89

Price/Free Cashflow

-16.62

MRUS Price/Sales (Trailing)

MRUS Profitability

EBT Margin

-345.30%

Return on Equity

-43.48%

Return on Assets

-34.02%

Free Cashflow Yield

-6.02%

MRUS Fundamentals

MRUS Revenue

Revenue (TTM)

43.9M

Rev. Growth (Yr)

-16.19%

Rev. Growth (Qtr)

-18.98%

MRUS Earnings

Earnings (TTM)

-154.9M

Earnings Growth (Yr)

26.62%

Earnings Growth (Qtr)

-161.4%

Breaking Down MRUS Revenue

52 Week Range

18.2141.92

(Low)(High)

Last 7 days

2.2%

Last 30 days

-6.3%

Last 90 days

23.1%

Trailing 12 Months

107.8%

How does MRUS drawdown profile look like?

MRUS Financial Health

Current Ratio

5.34

MRUS Investor Care

Shares Dilution (1Y)

24.96%

Diluted EPS (TTM)

-3.02

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	43.4M	41.2M	45.7M	43.9M
2022	52.4M	52.7M	45.6M	41.6M
2021	32.0M	38.3M	43.4M	49.1M
2020	28.6M	28.3M	28.7M	29.9M
2019	36.6M	34.8M	32.9M	31.1M
2018	26.0M	30.1M	34.3M	38.4M
2017	7.4M	12.2M	17.1M	21.9M
2016	0	0	0	2.5M
2015	0	0	0	1.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Merus NV

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 19, 2023	shuman harry	sold	-3,068	26.68	-115	vp controller, pao
Dec 15, 2023	silverman peter b.	acquired	-	-	22,386	coo & gc
Dec 15, 2023	silverman peter b.	sold	-559,650	25.00	-22,386	coo & gc
Dec 08, 2023	shuman harry	sold	-6,110	24.44	-250	vp controller, pao
Dec 01, 2023	shuman harry	acquired	-	-	2,500	vp controller, pao
Dec 01, 2023	shuman harry	sold	-14,133	24.58	-575	vp controller, pao
Jun 01, 2023	shuman harry	acquired	-	-	2,500	vp controller, pao
Jun 01, 2023	shuman harry	sold	-12,351	21.48	-575	vp controller, pao
Apr 14, 2023	iwicki mark t	acquired	534,679	7.26703	73,576	-
Apr 06, 2023	liu hui	acquired	770,948	7.86	98,085	evp, cbo & head of merus us

Which funds bought or sold MRUS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	Allspring Global Investments Holdings, LLC	new	-	71,598	71,598	-%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	added	11.06	129,489	287,697	0.01%
Apr 15, 2024	Medicxi Ventures Management (Jersey) Ltd	reduced	-26.94	8,641,330	52,641,300	11.72%
Apr 11, 2024	SANDERS MORRIS HARRIS LLC	unchanged	-	308,637	1,119,900	0.21%
Apr 10, 2024	CVA Family Office, LLC	unchanged	-	1,630	4,188	-%
Apr 05, 2024	GAMMA Investing LLC	added	100	761	1,261	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	unchanged	-	392	2,750	-%
Mar 11, 2024	VANGUARD GROUP INC	reduced	-15.13	-43,181	4,178,820	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	275	16,425,000	21,281,900	-%
Feb 22, 2024	SIERRA SUMMIT ADVISORS LLC	new	-	221,348	221,348	0.06%

Are Funds Buying or Selling MRUS?

Are funds buying MRUS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MRUS

No. of Funds

Unveiling Merus NV's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 25, 2024	incyte corp	6.9%	4,004,544	SC 13G
Mar 06, 2024	federated hermes, inc.	3.98%	2,297,700	SC 13G/A
Feb 14, 2024	commodore capital lp	8.2%	4,747,373	SC 13G/A
Feb 14, 2024	biotechnology value fund l p	2.5%	1,467,604	SC 13G/A
Feb 14, 2024	samlyn capital, llc	5.9%	3,412,410	SC 13G
Feb 12, 2024	flynn james e	5.23%	3,019,901	SC 13G/A
Feb 08, 2024	wellington management group llp	3.48%	2,009,403	SC 13G/A
Jan 18, 2024	federated hermes, inc.	6.30%	3,637,309	SC 13G/A
Aug 14, 2023	incyte corp	6.9%	4,004,544	SC 13D/A
Mar 10, 2023	federated hermes, inc.	4.62%	2,138,700	SC 13G/A

Recent SEC filings of Merus NV

View All Filings

Date Filed	Form Type	Document
Apr 11, 2024	DEFA14A	DEFA14A
Apr 10, 2024	DEF 14A	DEF 14A
Mar 29, 2024	PRE 14A	PRE 14A
Mar 25, 2024	SC 13G	Major Ownership Report
Mar 06, 2024	SC 13G/A	Major Ownership Report
Mar 06, 2024	8-K	Current Report
Feb 28, 2024	S-8	Employee Benefits Plan
Feb 28, 2024	S-3ASR	S-3ASR
Feb 28, 2024	10-K	Annual Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Merus NV)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	-1.39%	-19.31%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.44%	-28.86%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	5.41%	-4.57%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.99%	-29.65%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-10.10%	-42.90%	-11.39	15.18	425.83%	18.94%
BBIO	4.4B	-	-14.83%	70.74%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-7.99%	-0.08%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.49%	-30.64%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-7.01%	-17.50%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.67%	-6.03%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-13.72%	-45.61%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	-0.25%	294.45%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-18.06%	3.25%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	70.91%	57.98%	-0.24	2.14	-13.45%	66.37%

Merus NV News

Latest updates

Merus NV Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-19.0%	8,939,000	11,033,000	10,476,000	13,499,000	10,666,000	6,581,000	12,684,000	11,655,000	14,709,000	13,669,000	12,379,000	8,350,000	9,016,000	8,570,000	6,056,000	6,301,000	7,792,000	8,155,000	6,357,000	8,829,000	8,067,000
Operating Expenses	14.3%	56,481,000	49,401,000	44,361,000	50,251,000	64,329,000	54,776,000	43,791,000	38,728,000	37,574,000	36,189,000	35,181,000	30,139,000	31,526,000	26,674,000	21,752,000	25,869,000	30,733,000	21,535,000	18,982,000	18,540,000	-
S&GA Expenses	25.5%	15,796,000	12,591,000	16,063,000	15,386,000	15,283,000	12,469,000	12,695,000	11,753,000	10,823,000	10,171,000	10,569,000	9,333,000	9,720,000	9,136,000	8,043,000	8,882,000	11,131,000	8,024,000	8,214,000	6,741,000	-
R&D Expenses	10.5%	40,685,000	36,810,000	28,298,000	34,865,000	49,046,000	42,307,000	31,096,000	26,975,000	26,751,000	26,018,000	24,612,000	20,806,000	21,806,000	17,538,000	13,709,000	16,987,000	19,602,000	13,511,000	10,768,000	11,799,000	-
EBITDA Margin	9.8%	-3.40	-3.77	-4.25	-3.46	-3.11	-1.36	-0.99	-1.41	-1.33	-1.81	-2.27	-2.42	-2.80	-2.84	-2.41	-2.22	-	-	-	-	-
Income Taxes	-7.2%	1,037,000	1,118,000	1,494,000	-457,000	387,000	327,000	131,000	114,000	139,000	-11,000	62,000	49,000	198,000	177,000	31,000	97,000	-45,000	-54,000	71,000	222,000	-
Earnings Before Taxes	-170.0%	-59,116,000	-21,894,000	-30,539,000	-40,198,000	-81,585,000	-24,288,000	-5,583,000	-18,779,000	-14,282,000	-14,864,000	-27,326,000	-10,105,000	-27,766,000	-22,898,000	-17,943,000	-16,403,000	-25,471,000	-9,321,000	-13,304,000	-6,861,000	-
EBT Margin	9.5%	-3.45	-3.81	-4.28	-3.49	-3.13	-1.38	-1.02	-1.44	-1.36	-1.84	-2.30	-2.46	-2.84	-2.88	-2.44	-2.25	-	-	-	-	-
Net Income	-161.4%	-60,153,000	-23,012,000	-32,033,000	-39,741,000	-81,972,000	-24,615,000	-5,714,000	-18,893,000	-14,421,000	-14,853,000	-27,388,000	-10,154,000	-27,964,000	-23,075,000	-17,974,000	-16,500,000	-25,426,000	-9,267,000	-13,375,000	-7,083,000	-
Net Income Margin	8.9%	-3.53	-3.87	-4.33	-3.50	-3.15	-1.39	-1.02	-1.44	-1.36	-1.85	-2.31	-2.47	-2.86	-2.89	-2.44	-2.26	-	-	-	-	-
Free Cashflow	-31.7%	-36,322,000	-27,569,000	-41,935,000	-40,363,000	-32,568,000	-43,587,000	-34,592,000	-46,739,000	-31,931,000	-23,352,000	-24,400,000	19,186,000	-24,765,000	-12,043,000	-18,972,000	-25,408,000	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-7.5%	455	492	364	339	377	415	445	418	457	356	380	398	231	213	224	238	263	232	201	227	253
Current Assets	-8.9%	369	405	283	258	306	368	399	380	424	320	367	386	218	201	211	225	247	-	177	-	243
Cash Equivalents	-15.6%	204	242	101	103	148	191	214	195	241	159	311	327	163	139	152	166	198	134	150	157	165
Net PPE	-0.3%	12.00	12.00	13.00	13.00	12.00	7.00	6.00	4.00	4.00	3.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	-	3.00	-	3.00
Liabilities	0.4%	99.00	99.00	106	121	129	116	118	120	140	150	160	161	129	129	123	123	132	128	124	136	147
Current Liabilities	7.4%	69.00	64.00	66.00	75.00	79.00	64.00	60.00	62.00	72.00	72.00	64.00	53.00	47.00	45.00	38.00	36.00	37.00	-	30.00	-	34.00
Shareholder's Equity	-9.4%	356	393	257	218	247	299	327	297	316	206	219	237	102	85.00	100	115	131	77.00	88.00	98.00	106
Retained Earnings	-8.7%	-753	-692	-669	-637	-598	-516	-491	-485	-466	-452	-437	-410	-400	-372	-349	-331	-314	-	-190	-	-259
Additional Paid-In Capital	0.7%	1,126	1,118	949	877	871	865	849	794	788	657	650	643	490	449	446	444	441	-	-	-	360
Shares Outstanding	0.2%	58.00	58.00	50.00	46.00	46.00	-	43,781	43,490	-	-	-	36.00	-	-	-	-	29.00	23.00	23.00	23.00	23.00
Float	-	-	-	1,304	-	-	-	1,034	-	-	-	730	-	-	-	465	-	-	-	343	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-32.0%	-36,348	-27,530	-41,586	-36,743	-30,512	-41,256	-31,734	-46,397	-31,598	-23,075	-24,297	19,343	-24,336	-11,697	-18,608	-25,260	-19,744	-14,024	-15,770	-13,510	-
Share Based Compensation	-8.3%	6,708	7,315	6,453	5,750	6,014	6,525	6,662	5,334	4,801	4,331	4,559	3,400	3,045	2,844	1,192	2,291	2,646	2,068	1,860	1,260	-
Cashflow From Investing	-126.4%	-2,117	8,022	-24,518	-8,407	856	-1,141	4,054	-967	-15,759	-133,917	5,727	-2,674	5,900	-6,108	2,710	-3,988	4,148	4,455	7,714	7,855	-
Cashflow From Financing	-99.1%	1,500	162,402	65,967	217	-215	9,876	48,199	879	127,042	2,595	1,861	150,457	38,769	22.00	291	438	74,184	17.00	3.00	28.00	-
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	285	-	-	-	-	-	-	-	-	-

MRUS Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Total revenue	$ 43,947	$ 41,586	$ 49,107
Operating expenses:
Research and development	140,658	149,424	98,187
General and administrative	59,836	52,200	40,896
Total operating expenses	200,494	201,624	139,083
Operating loss	(156,547)	(160,038)	(89,976)
Other income (loss), net:
Interest (expense) income, net	14,510	2,722	(129)
Foreign exchange (losses) gains, net	(9,710)	26,022	24,663
Other (losses) gains, net		1,059	(1,135)
Total other income (loss), net	4,800	29,803	23,399
Loss before income tax expense	(151,747)	(130,235)	(66,577)
Income tax expense	3,192	959	239
Net loss	(154,939)	(131,194)	(66,816)
Other comprehensive income (loss):
Currency translation adjustment	7,915	(21,227)	(18,292)
Comprehensive loss	$ (147,024)	$ (152,421)	$ (85,108)
Net loss per share attributable to common stockholders:
Basic	$ (3)	$ (2.92)	$ (1.73)
Diluted	$ (3)	$ (2.92)	$ (1.73)
Weighted-average common shares outstanding:
Basic	51,605,444	44,919,084	38,638,434
Diluted	51,605,444	44,919,084	38,638,434
Collaboration Revenue [Member]
Total revenue from contracts with customers	$ 43,947	$ 41,586	$ 19,503
Collaboration Revenue (Related Party) [Member]
Total revenue from contracts with customers	$ 0	$ 0	$ 29,604

MRUS Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 204,246	$ 147,749
Marketable securities	150,130	142,480
Accounts receivable	2,429	4,051
Prepaid expenses and other current assets	12,009	12,163
Total current assets	368,814	306,443
Marketable securities	57,312	36,457
Property and equipment, net	12,135	12,222
Operating lease right-of-use assets	11,362	12,618
Intangible assets, net	1,800	1,950
Deferred tax assets	1,199	2,041
Other assets	2,872	4,811
Total assets	455,494	376,542
Current liabilities:
Accounts payable	4,602	9,834
Accrued expenses and other liabilities	38,482	35,590
Income taxes payable	1,646	2,400
Current portion of lease obligation	1,674	1,684
Current portion of deferred revenue	22,685	29,418
Total current liabilities	69,089	78,926
Lease obligation	10,488	11,790
Deferred revenue, net of current portion	19,574	38,771
Total liabilities	99,151	129,487
Commitments and contingencies (Note 10)
Stockholders’ equity:
Common shares, EUR 0.09 par value; 67,500,000 and 67,500,000 shares authorized at December 31, 2023 and 2022, respectively; 57,825,879 46,310,589 shares issued and outstanding at December 31, 2023 and 2022, respectively	5,883	4,751
Additional paid-in capital	1,126,054	870,874
Accumulated deficit	(753,061)	(598,122)
Accumulated other comprehensive (loss) income	(22,533)	(30,448)
Total stockholders’ equity	356,343	247,055
Total liabilities and stockholders’ equity	$ 455,494	$ 376,542

About Merus NV

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

CEO	Dr. Sven Ante Lundberg M.D.
WEBSITE	merus.nl
INDUSTRY	Biotechnology
EMPLOYEES	164

Merus NV Frequently Asked Questions

What is the ticker symbol for Merus NV? What does MRUS stand for in stocks?

MRUS is the stock ticker symbol of Merus NV. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Merus NV (MRUS)?

As of Wed Apr 24 2024, market cap of Merus NV is 2.43 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MRUS stock?

You can check MRUS's fair value in chart for subscribers.

What is the fair value of MRUS stock?

You can check MRUS's fair value in chart for subscribers. The fair value of Merus NV is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Merus NV is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MRUS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Merus NV a good stock to buy?

The fair value guage provides a quick view whether MRUS is over valued or under valued. Whether Merus NV is cheap or expensive depends on the assumptions which impact Merus NV's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MRUS.

What is Merus NV's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, MRUS's PE ratio (Price to Earnings) is -15.68 and Price to Sales (PS) ratio is 55.27. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MRUS PE ratio will change depending on the future growth rate expectations of investors.